top of page

Novo Nordisk's sales increased by 29% to DKK 107.7 billion

Novo Nordisk's sales increased by 29% in Danish kroner and by 30% at constant exchange rates to DKK 107.7 billion in the first six months of 2023

Financial report for the period 1 January 2023 to 30 June 2023, 10 August 2023

  • Operating profit increased by 30% in Danish kroner and by 32% at constant exchange rates (CER) to DKK 48.9 billion.

  • Sales in North America Operations increased by 45% in Danish kroner (44% at CER). Sales in International Operations increased by 14% in Danish kroner (17% at CER).

  • Sales within Diabetes and Obesity care increased by 36% in Danish kroner to DKK 99.0 billion (37% at CER), mainly driven by GLP-1 diabetes sales growth of 49% in Danish kroner (50% at CER) and Obesity care growing by 158% in Danish Kroner to DKK 18.1 billion (157% at CER) . Rare disease sales decreased by 18% in both Danish kroner and CER reflecting a temporary reduction in manufacturing output.

  • In August 2023, Novo Nordisk announced that semaglutide 2.4 mg statistically significantly reduced the risk of major adverse cardiovascular events in the SELECT cardiovascular outcomes trial. Further, the phase 3 obesity trials OASIS 1 and STEP HFpEF were successfully completed

  • For the 2023 outlook, sales and operating profit growth at CER are now expected to be 27-33% and 31-37%, respectively. Sales and operating profit growth reported in Danish kroner are expected to be 6 and 9 percentage points lower than at CER, respectively.

all images ©

Read our Summer Issue

See Haute couture from

Dior, Alexis Mabille, Georges Hobeika, Zuhair Murad, Valentino and more

Explore Moralmoda Art Culture Lifestyle Travel Business Interviews Events ​ Get in touch About us Contacts Subscribe

bottom of page